CAFs (Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC): a Phase I/II Study
Latest Information Update: 15 Jul 2024
At a glance
- Drugs Atezolizumab (Primary) ; Pirfenidone (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms CAFs
- 04 Jun 2024 Results measuring circulating levels of TGF beta and investigate the expression of CAF-related proteins, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 07 Sep 2023 Planned End Date changed from 1 Aug 2024 to 1 Aug 2025.
- 07 Sep 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Aug 2024.